6 results match your criteria: "BetaPlus Center for Reproductive Medicine[Affiliation]"
Eur J Obstet Gynecol Reprod Biol
November 2024
BetaPlus Center for Reproductive Medicine, Ulica Charlesa Darwina 6H, 10 000 Zagreb, Croatia. Electronic address:
Objective(s): Assisted reproductive technology (ART) Centers and laboratories perform complex tasks with patients and their gametes/embryos daily. The degree of problems/non-conformances in such surroundings must be minimized at zero point. This study aimed to establish the proper risk management system with well-defined process steps to prevent and eliminate problems/non-conformances.
View Article and Find Full Text PDFJ Assist Reprod Genet
January 2020
BetaPlus Center for Reproductive Medicine, Avenija Veceslava Holjevca 23, 10 000, Zagreb, Croatia.
Purpose: To assess the variability of meiotic segregation patterns in sperm of Robertsonian translocation (RobT) carrier t(21;22) and present effect on reproductive outcome.
Methods: Infertile couple enrolled in IVF/ICSI program. Sperm chromosomal segregation analysis was done using FISH; preimplantation genetic testing for aneuploids (PGT-A) was performed by NGS.
Reprod Biol
September 2018
Department of Immunological and Molecular Diagnostics, University Hospital for Infectious Diseases "Dr. Fran Mihaljević", Mirogojska 8, 10 000 Zagreb, Croatia.
The aim of this study was to analyse the presence of vascular endothelial growth factor (VEGF) and interferon alpha (IFN-α) in the follicular fluid (FF) and their possible influence, as pro-angiogenic or anti-angiogenic factors, on in vitro fertilization outcome. The concentrations of VEGF and IFN-α were correlated with oocyte and embryo quality, concentrations of hormones in the serum, perifollicular blood flow and endometrial thickness. VEGF was detected in all FF samples (median 706.
View Article and Find Full Text PDFHum Reprod
November 2013
BetaPlus Center for Reproductive Medicine, Avenija Veceslava Holjevca 23, 10000 Zagreb, Croatia and.
Study Question: Is a vaginal preparation of sildenafil citrate capable of alleviating acute menstrual pain in patients with primary dysmenorrhea (PD)?
Summary Answer: A vaginal preparation of sildenafil citrate is capable of alleviating acute menstrual pain in patients with PD with no observed adverse effects.
What Is Known Already: Oral preparations of nitric oxide (NO) donor drugs augment relaxant effects of NO on myometrial cells, reverse the vasoconstriction caused by prostaglandins and successfully alleviate pain, but the incidence of side effects is too high for routine clinical use. Sildenafil citrate inhibits type 5-specific phosphodiesterase (PDE5), thus preventing the degradation of cyclic guanosine monophosphate (cGMP) in the muscle and augmenting the vasodilatory effects of NO.
Objective: To estimate whether continuous oral contraceptive pills (OCPs) will result in more pain relief in primary dysmenorrhea patients than cyclic OCPs, which induce withdrawal bleeding with associated pain and symptoms.
Methods: We conducted a double-blind, randomized, controlled trial comparing continuous to a cyclic 21-7 OCP regimen (gestodene 0.075 mg and ethinyl estradiol 20 microgram) for 6 months in 38 primary dysmenorrhea patients.
Obstet Gynecol
October 2011
BetaPlus Center for Reproductive Medicine, Zagreb, Croatia.
Objective: To estimate whether women with polycystic ovary syndrome (PCOS) will display ambient hyperglycemia (as measured by continuous glucose monitoring) early in pregnancy that progressively exacerbates with advancing pregnancy.
Methods: This was a case-control study during singleton pregnancies of 17 women with PCOS and 17 healthy women. A 75-g oral glucose tolerance test (OGTT) followed by 24-hour continuous glucose monitoring was obtained four times throughout the pregnancy (visit 1: 6-10 weeks; visit 2: 12-16 weeks; visit 3: 24-28 weeks; visit 4: 34-38 weeks).